Compare ARAI & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARAI | LSTA |
|---|---|---|
| Founded | 2020 | 1980 |
| Country | United States | United States |
| Employees | 51 | N/A |
| Industry | Diversified Commercial Services | Misc Health and Biotechnology Services |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.3M | 28.9M |
| IPO Year | N/A | 2000 |
| Metric | ARAI | LSTA |
|---|---|---|
| Price | $0.71 | $3.11 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $12.00 | ★ $15.00 |
| AVG Volume (30 Days) | ★ 2.4M | 62.0K |
| Earning Date | 04-15-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.42 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $35,283,868.00 |
| Revenue This Year | $800.66 | N/A |
| Revenue Next Year | $650.00 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 56.90 |
| 52 Week Low | $0.51 | $1.81 |
| 52 Week High | $15.50 | $5.07 |
| Indicator | ARAI | LSTA |
|---|---|---|
| Relative Strength Index (RSI) | 43.33 | 33.44 |
| Support Level | $0.65 | $2.75 |
| Resistance Level | $0.81 | $3.43 |
| Average True Range (ATR) | 0.06 | 0.14 |
| MACD | 0.00 | 0.05 |
| Stochastic Oscillator | 19.95 | 10.53 |
Arrive AI Inc is a technology company. Its patented Autonomous Last Mile (ALM) platform enables secure, efficient delivery to and from a smart, AI-powered mailbox-whether by drone, ground robot, or human courier. The platform provides real-time tracking, smart logistics alerts, and advance chain-of-custody controls to support shippers, delivery services, and autonomous networks. By combining artificial intelligence with autonomous technology, Arrive AI makes the exchange of goods between people, robots, and drones frictionless and convenient. Its system integrates with smart home devices such as doorbells, lighting, and security systems to streamline the entire last-mile delivery experience.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.